These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 1547193)
21. Plasma high density lipoprotein is increased in man when low density lipoprotein (LDL) is lowered by LDL-pheresis. Parker TS; Gordon BR; Saal SD; Rubin AL; Ahrens EH Proc Natl Acad Sci U S A; 1986 Feb; 83(3):777-81. PubMed ID: 3511474 [TBL] [Abstract][Full Text] [Related]
22. Isolation of lipoprotein (a) using the regenerate of a dextran sulfate cellulose LDL apheresis system. Gross E; März W; Siekmeier R; Scharrer I; Gross W Protein Expr Purif; 1994 Apr; 5(2):112-7. PubMed ID: 8054842 [TBL] [Abstract][Full Text] [Related]
23. Advances in LDL-apheresis for the treatment of severe hypercholesterolemia. Gordon BR; Saal SD Curr Opin Lipidol; 1994 Feb; 5(1):69-73. PubMed ID: 15559033 [TBL] [Abstract][Full Text] [Related]
24. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis. Donner MG; Parhofer KG; Richter WO; Schwandt P Metabolism; 1999 Jul; 48(7):881-6. PubMed ID: 10421230 [TBL] [Abstract][Full Text] [Related]
25. Further resolution and comparison of the heterogeneity of plasma low-density lipoproteins in human hyperlipoproteinemias: type III hyperlipoproteinemia, hypertriglyceridemia and familial hypercholesterolemia. Luc G; de Gennes JL; Chapman MJ Atherosclerosis; 1988 Jun; 71(2-3):143-56. PubMed ID: 3401287 [TBL] [Abstract][Full Text] [Related]
26. Blood antioxidants (vitamin E and beta-carotene) in long-term low density lipoprotein apheresis. Assogba U; Lepage S; Bruckert E; Bonnefont-Rousselot D; Dairou F; de Gennes JL; Delattre J Clin Chim Acta; 1995 Mar; 235(2):147-57. PubMed ID: 7554269 [TBL] [Abstract][Full Text] [Related]
27. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Napoli C; Ambrosio G; Scarpato N; Corso G; Palumbo G; D'Armiento FP; Mancini FP; Malorni A; Formisano S; Ruocco A; Calí A; Chiariello M Am Heart J; 1997 May; 133(5):585-95. PubMed ID: 9141382 [TBL] [Abstract][Full Text] [Related]
28. Lipoproteins do not modulate the tissue factor activity, plasminogen activator or tumour necrosis factor production induced by lipopolysaccharide stimulation of human monocytes. Schlichting E; Henriksen T; Lyberg T Scand J Clin Lab Invest; 1994 Oct; 54(6):465-73. PubMed ID: 7809580 [TBL] [Abstract][Full Text] [Related]
29. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy. Yamamoto A; Harada-Shiba M; Kawaguchi A; Oi K; Kubo H; Sakai S; Mikami Y; Imai T; Ito T; Kato H; Endo M; Sato I; Suzuki Y; Hori H Atherosclerosis; 2000 Nov; 153(1):89-98. PubMed ID: 11058703 [TBL] [Abstract][Full Text] [Related]
30. Treatment of familial hypocholesterolemia by means of specific immunoadsorption. Borberg H; Gaczkowski A; Hombach V; Oette K; Stoffel W J Clin Apher; 1988; 4(2-3):59-65. PubMed ID: 3294230 [No Abstract] [Full Text] [Related]
31. LDL-apheresis in two patients with extremely elevated lipoprotein (a) levels. Bambauer R; Schiel R; Keller HE; Latza R Int J Artif Organs; 1995 May; 18(5):286-90. PubMed ID: 8567105 [TBL] [Abstract][Full Text] [Related]
32. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis. Hussein H; Saheb S; Couturier M; Atassi M; Orsoni A; Carrié A; Therond P; Chantepie S; Robillard P; Bruckert E; Chapman MJ; Kontush A J Clin Lipidol; 2016; 10(1):124-33. PubMed ID: 26892129 [TBL] [Abstract][Full Text] [Related]
33. [LDL apheresis--an effective treatment of homozygous familial hypercholesterolemia]. Kauppinen-Mäkelin R; Koivisto V; Virtanen KS; Taskinen MR; Miettinen T Duodecim; 1990; 106(21):1465-70. PubMed ID: 1364677 [No Abstract] [Full Text] [Related]
34. Changes in serum afamin and vitamin E levels after selective LDL apheresis. Varga VE; Lőrincz H; Szentpéteri A; Juhász L; Seres I; Paragh G; Balla J; Paragh G; Harangi M J Clin Apher; 2018 Oct; 33(5):569-575. PubMed ID: 30247793 [TBL] [Abstract][Full Text] [Related]
35. Effects of LDL-immunoapheresis on plasma concentrations of vitamin E and carotenoids in patients with familial hypercholesterolemia. Cauza E; Jansen M; Resch U; Dunky A; Derfler K; Winklhofer-Roob BM; Kostner K J Clin Apher; 2004; 19(4):174-9. PubMed ID: 15597350 [TBL] [Abstract][Full Text] [Related]
36. Effect of low-density lipoproteins on apolipoprotein AI kinetics in heterozygous familial hypercholesterolemia. Frénais R; Maugeais C; Ouguerram K; Zaïr Y; Bard JM; Charbonnel B; Magot T; Krempf M Metabolism; 2001 Jun; 50(6):635-9. PubMed ID: 11398137 [TBL] [Abstract][Full Text] [Related]
37. LDL-apheresis as long-term treatment in severe hyperlipidemia using differing methods. Bambauer R; Schiel R; Latza R; Schneidewind JM ASAIO J; 1999; 45(5):408-12. PubMed ID: 10503616 [TBL] [Abstract][Full Text] [Related]
38. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Stoffel W; Borberg H; Greve V Lancet; 1981 Nov; 2(8254):1005-7. PubMed ID: 6118475 [TBL] [Abstract][Full Text] [Related]
39. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis. Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745 [TBL] [Abstract][Full Text] [Related]
40. [Apheresis of low-density lipids in the treatment of hereditary hypercholesterolemia]. Konovalov GA; Kukharchuk VV; Sinitsin VV; Trakht IN; Adamova IIu Vutr Boles; 1989; 28(4):133-6. PubMed ID: 2596087 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]